Skip to main content
Erschienen in: Familial Cancer 4/2019

10.07.2019 | Original Article

Lynch syndrome with exclusive skin involvement: time to consider a molecular definition?

verfasst von: Alessandro Vaisfeld, Martina Calicchia, Maria Grazia Pomponi, Emanuela Lucci-Cordisco, Luca Reggiani-Bonetti, Maurizio Genuardi

Erschienen in: Familial Cancer | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Muir–Torre syndrome (MTS) is clinically characterized by the occurrence of skin, usually sebaceous, and visceral tumors in the same individual. The most common underlying mechanism is a constitutional defect of the mismatch repair (MMR) genes that cause Lynch syndrome (LS). Herewithin we report on a 76 years-old male patient heterozygous for a pathogenic MSH2 missense substitution who presented with a striking cutaneous phenotype in the absence of typical LS visceral tumors. The patient developed 20 skin tumors, including sebaceous adenomas/carcinomas and keratoacanthomas. Two skin tumors showed immunohistochemical loss of MSH2 and MSH6 expression. There was no apparent family history of neoplasia. Based on the variable involvement of the skin and internal organs, we suggest that the definition of tumor associations that are often observed as variants of inherited tumor syndromes, such as MTS, should be guided by the underlying molecular bases. In addition, the presence of multiple sebaceous tumors, especially if showing MMR deficiency, appears to be a very strong indicator of a constitutional MMR gene defect. The reasons underlying the high phenotypic variability of cutaneous phenotypes associated with constitutional MMR defects are yet to be determined.
Literatur
1.
Zurück zum Zitat Muir EG, Bell AJ, Barlow KA (1967) Multiple primary carcinomata of the colon, duodenum, and larynx associated with keratoacanthomata of the face. Br J Surg 54:191–195CrossRef Muir EG, Bell AJ, Barlow KA (1967) Multiple primary carcinomata of the colon, duodenum, and larynx associated with keratoacanthomata of the face. Br J Surg 54:191–195CrossRef
2.
4.
Zurück zum Zitat Akhtar S, Oza KK, Khan SA, Wright J (1999) Muir-Torre syndrome: case report of a patient with concurrent jejunal and ureteral cancer and a review of the literature. J Am Acad Dermatol 41:681–686CrossRef Akhtar S, Oza KK, Khan SA, Wright J (1999) Muir-Torre syndrome: case report of a patient with concurrent jejunal and ureteral cancer and a review of the literature. J Am Acad Dermatol 41:681–686CrossRef
6.
Zurück zum Zitat Cohen PR, Kohn SR, Kurzrock R (1991) Association of sebaceous gland tumors and internal malignancy: the Muir-Torre syndrome. Am J Med 90:606–613CrossRef Cohen PR, Kohn SR, Kurzrock R (1991) Association of sebaceous gland tumors and internal malignancy: the Muir-Torre syndrome. Am J Med 90:606–613CrossRef
11.
Zurück zum Zitat Kruse R, Rütten A, Lamberti C, Hosseiny-Malayeri HR, Wang Y, Ruelfs C, Jungck M, Mathiak M, Ruzicka T, Hartschuh W, Bisceglia M, Friedl W, Propping P (1998) Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria. Am J Hum Genet 63:63–70. https://doi.org/10.1086/301926 CrossRefPubMedPubMedCentral Kruse R, Rütten A, Lamberti C, Hosseiny-Malayeri HR, Wang Y, Ruelfs C, Jungck M, Mathiak M, Ruzicka T, Hartschuh W, Bisceglia M, Friedl W, Propping P (1998) Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria. Am J Hum Genet 63:63–70. https://​doi.​org/​10.​1086/​301926 CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, Hogervorst FB, Hoogerbrugge N, Spurdle AB, Tavtigian SV, IARC Unclassified Genetic Variants Working Group (2008) Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 29:1282–1291. https://doi.org/10.1002/humu.20880 CrossRefPubMedPubMedCentral Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, Hogervorst FB, Hoogerbrugge N, Spurdle AB, Tavtigian SV, IARC Unclassified Genetic Variants Working Group (2008) Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 29:1282–1291. https://​doi.​org/​10.​1002/​humu.​20880 CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Engel C, Loeffler M, Steinke V, Rahner N, Holinski-Feder E, Dietmaier W, Schackert HK, Goergens H, von Knebel Doeberitz M, Goecke TO, Schmiegel W, Buettner R, Moeslein G, Letteboer TG, Gómez García E, Hes FJ, Hoogerbrugge N, Menko FH, van Os TA, Sijmons RH, Wagner A, Kluijt I, Propping P, Vasen HF (2012) Risks of less common cancers in proven mutation carriers with Lynch syndrome. J Clin Oncol 30:4409–4415. https://doi.org/10.1200/JCO.2012.43.2278 CrossRefPubMed Engel C, Loeffler M, Steinke V, Rahner N, Holinski-Feder E, Dietmaier W, Schackert HK, Goergens H, von Knebel Doeberitz M, Goecke TO, Schmiegel W, Buettner R, Moeslein G, Letteboer TG, Gómez García E, Hes FJ, Hoogerbrugge N, Menko FH, van Os TA, Sijmons RH, Wagner A, Kluijt I, Propping P, Vasen HF (2012) Risks of less common cancers in proven mutation carriers with Lynch syndrome. J Clin Oncol 30:4409–4415. https://​doi.​org/​10.​1200/​JCO.​2012.​43.​2278 CrossRefPubMed
17.
Zurück zum Zitat Vasen HFA, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, Bernstein I, Bertario L, Burn J, Capella G, Colas C, Engel C, Frayling IM, Genuardi M, Heinimann K, Hes FJ, Hodgson SV, Karagiannis JA, Lalloo F, Lindblom A, Mecklin JP, Møller P, Myrhoj T, Nagengast FM, Parc Y, Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Sijmons RH, Tejpar S, Thomas HJW, Rahner N, Wijnen JT, Järvinen HJ, Möslein G, the Mallorca Group (2013) Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 62:812–823. https://doi.org/10.1136/gutjnl-2012-304356 CrossRefPubMedPubMedCentral Vasen HFA, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, Bernstein I, Bertario L, Burn J, Capella G, Colas C, Engel C, Frayling IM, Genuardi M, Heinimann K, Hes FJ, Hodgson SV, Karagiannis JA, Lalloo F, Lindblom A, Mecklin JP, Møller P, Myrhoj T, Nagengast FM, Parc Y, Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Sijmons RH, Tejpar S, Thomas HJW, Rahner N, Wijnen JT, Järvinen HJ, Möslein G, the Mallorca Group (2013) Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 62:812–823. https://​doi.​org/​10.​1136/​gutjnl-2012-304356 CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Thompson BA, Spurdle AB, Plazzer JP, Greenblatt MS, Akagi K, Al-Mulla F, Bapat B, Bernstein I, Capellá G, den Dunnen JT, du Sart D, Fabre A, Farrell MP, Farrington SM, Frayling IM, Frebourg T, Goldgar DE, Heinen CD, Holinski-Feder E, Kohonen-Corish M, Robinson KL, Leung SY, Martins A, Moller P, Morak M, Nystrom M, Peltomaki P, Pineda M, Qi M, Ramesar R, Rasmussen LJ, Royer-Pokora B, Scott RJ, Sijmons R, Tavtigian SV, Tops CM, Weber T, Wijnen J, Woods MO, Macrae F, Genuardi M (2014) Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nat Genet 46:107–115. https://doi.org/10.1038/ng.2854 CrossRefPubMed Thompson BA, Spurdle AB, Plazzer JP, Greenblatt MS, Akagi K, Al-Mulla F, Bapat B, Bernstein I, Capellá G, den Dunnen JT, du Sart D, Fabre A, Farrell MP, Farrington SM, Frayling IM, Frebourg T, Goldgar DE, Heinen CD, Holinski-Feder E, Kohonen-Corish M, Robinson KL, Leung SY, Martins A, Moller P, Morak M, Nystrom M, Peltomaki P, Pineda M, Qi M, Ramesar R, Rasmussen LJ, Royer-Pokora B, Scott RJ, Sijmons R, Tavtigian SV, Tops CM, Weber T, Wijnen J, Woods MO, Macrae F, Genuardi M (2014) Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nat Genet 46:107–115. https://​doi.​org/​10.​1038/​ng.​2854 CrossRefPubMed
19.
Zurück zum Zitat Thompson BA, Goldgar DE, Paterson C, Clendenning M, Walters R, Arnold S, Parsons MT, Michael DW, Gallinger S, Haile RW, Hopper JL, Jenkins MA, Lemarchand L, Lindor NM, Newcomb PA, Thibodeau SN, Registry Colon Cancer Family, Young JP, Buchanan DD, Tavtigian SV, Spurdle AB (2013) A multifactorial likelihood model for MMR gene variant classification incorporating probabilities based on sequence bioinformatics and tumor characteristics: a report from the Colon Cancer Family Registry. Hum Mutat 34:200–209. https://doi.org/10.1002/humu.22213 CrossRefPubMed Thompson BA, Goldgar DE, Paterson C, Clendenning M, Walters R, Arnold S, Parsons MT, Michael DW, Gallinger S, Haile RW, Hopper JL, Jenkins MA, Lemarchand L, Lindor NM, Newcomb PA, Thibodeau SN, Registry Colon Cancer Family, Young JP, Buchanan DD, Tavtigian SV, Spurdle AB (2013) A multifactorial likelihood model for MMR gene variant classification incorporating probabilities based on sequence bioinformatics and tumor characteristics: a report from the Colon Cancer Family Registry. Hum Mutat 34:200–209. https://​doi.​org/​10.​1002/​humu.​22213 CrossRefPubMed
20.
Zurück zum Zitat Roberts ME, Riegert-Johnson DL, Thomas BC, Rumilla KM, Thomas CS, Heckman MG, Purcell JU, Krishna M, Hanson NB, Leppig KA, Lim J, Cappel MA (2014) A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome. Genet Med 16:711716. https://doi.org/10.1038/gim.2014.19 CrossRef Roberts ME, Riegert-Johnson DL, Thomas BC, Rumilla KM, Thomas CS, Heckman MG, Purcell JU, Krishna M, Hanson NB, Leppig KA, Lim J, Cappel MA (2014) A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome. Genet Med 16:711716. https://​doi.​org/​10.​1038/​gim.​2014.​19 CrossRef
21.
26.
Zurück zum Zitat Ollila S, Sarantaus L, Kariola R, Chan P, Hampel H, Holinski-Feder E, Macrae F, Kohonen-Corish M, Gerdes AM, Peltomäki P, Mangold E, de la Chapelle A, Greenblatt M, Nyström M (2006) Pathogenicity of MSH2 missense mutations is typically associated with impaired repair capability of the mutated protein. Gastroenterology 131:1408–1417. https://doi.org/10.1053/j.gastro.2006.08.044 CrossRefPubMed Ollila S, Sarantaus L, Kariola R, Chan P, Hampel H, Holinski-Feder E, Macrae F, Kohonen-Corish M, Gerdes AM, Peltomäki P, Mangold E, de la Chapelle A, Greenblatt M, Nyström M (2006) Pathogenicity of MSH2 missense mutations is typically associated with impaired repair capability of the mutated protein. Gastroenterology 131:1408–1417. https://​doi.​org/​10.​1053/​j.​gastro.​2006.​08.​044 CrossRefPubMed
27.
Zurück zum Zitat Rumelt S, Hogan NR, Rubin PA, Jakobiec FA (1998) Four-eyelid sebaceous cell carcinoma following irradiation. Arch Ophthalmol 116:1670–1672CrossRef Rumelt S, Hogan NR, Rubin PA, Jakobiec FA (1998) Four-eyelid sebaceous cell carcinoma following irradiation. Arch Ophthalmol 116:1670–1672CrossRef
28.
Zurück zum Zitat Hood IC, Qizilbash AH, Salama SS, Young JE, Archibald SD (1986) Sebaceous carcinoma of the face following irradiation. Am J Dermatopathol 8:505–508CrossRef Hood IC, Qizilbash AH, Salama SS, Young JE, Archibald SD (1986) Sebaceous carcinoma of the face following irradiation. Am J Dermatopathol 8:505–508CrossRef
32.
Zurück zum Zitat North JP, Golovato J, Vaske CJ, Sanborn JZ, Nuyen A, Wu W, Goode B, Stevers M, McMullen K, Perez White BE, Collisson EA, Bloomer M, Solomon DA, Benz SC, Cho RJ (2018) Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma. Nat Commun 14:1894. https://doi.org/10.1038/s41467-018-04008-y CrossRef North JP, Golovato J, Vaske CJ, Sanborn JZ, Nuyen A, Wu W, Goode B, Stevers M, McMullen K, Perez White BE, Collisson EA, Bloomer M, Solomon DA, Benz SC, Cho RJ (2018) Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma. Nat Commun 14:1894. https://​doi.​org/​10.​1038/​s41467-018-04008-y CrossRef
33.
Zurück zum Zitat Paraf F, Jothy S, Van Meir EG (1997) Brain tumor-polyposis syndrome: two genetic diseases? J Clin Oncol 15:2744–2758CrossRef Paraf F, Jothy S, Van Meir EG (1997) Brain tumor-polyposis syndrome: two genetic diseases? J Clin Oncol 15:2744–2758CrossRef
34.
Zurück zum Zitat Lynch HT, Lynch PM, Pester J, Fusaro RM (1981) The cancer family syndrome. Rare cutaneous phenotypic linkage of Torre’s syndrome. Arch Intern Med 141:607–611CrossRef Lynch HT, Lynch PM, Pester J, Fusaro RM (1981) The cancer family syndrome. Rare cutaneous phenotypic linkage of Torre’s syndrome. Arch Intern Med 141:607–611CrossRef
Metadaten
Titel
Lynch syndrome with exclusive skin involvement: time to consider a molecular definition?
verfasst von
Alessandro Vaisfeld
Martina Calicchia
Maria Grazia Pomponi
Emanuela Lucci-Cordisco
Luca Reggiani-Bonetti
Maurizio Genuardi
Publikationsdatum
10.07.2019
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 4/2019
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-019-00139-3

Weitere Artikel der Ausgabe 4/2019

Familial Cancer 4/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.